Piramal Pharma, a global pharmaceutical company, has announced its standalone and consolidated results for the Quarter 1 of 2024.
Highlights include:
- Operations revenue grew by 12% YoY in Q1FY25, driven by robust growth in the CDMO and ICH businesses
- EBITDA grew by 31% YoY with an EBITDA margin of 11%, which was driven by cost optimisation measures and a superior revenue mix
- The successful FDA inspections at its Lexington facility
- Piramal named as one of the top sustainable organisational the Times Now Global Sustainability Alliance event
Chair of Piramal Pharma, Nandini Piramal said: “We have had a good start to the financial year with a steady all-round performance. We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favourable revenue mix and cost optimisation initiatives. Our CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing.”
“We are also seeing good demand for our differentiated offerings with increase in customer enquiries and visits. In our CHG business, our planned expansion for inhalation anaesthesia portfolio is on track and is expected to get commercialised in FY26. Our India Consumer Healthcare business is also delivering steady growth driven by power brands and strong traction in e-commerce channel.”
